Welcome to our dedicated page for Cullinan Oncology SEC filings (Ticker: CGEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cullinan Therapeutics, Inc. (Nasdaq: CGEM) SEC filings page on Stock Titan provides access to the company’s public disclosures filed with the U.S. Securities and Exchange Commission. These documents include Current Reports on Form 8-K, which Cullinan uses to report material events such as clinical data updates, financial results, regulatory milestones, and significant corporate actions related to its biopharmaceutical business.
For a clinical-stage company like Cullinan, SEC filings are a primary source of detail on the development of its T cell engager and targeted therapy programs. Recent 8-K filings describe updated Phase 1 data for CLN-049, an FLT3xCD3 bispecific T cell engager in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, including response rates, safety findings, and the impact of FDA Fast Track designation. Other filings summarize financial results, cash and investment levels, and expectations for cash runway under the company’s operating plan.
Filings may also reference Cullinan’s work in autoimmune diseases with CLN-978, a CD19xCD3 bispecific T cell engager, and its collaboration with Taiho Oncology and Taiho Pharmaceutical on zipalertinib (CLN-081/TAS6417), an EGFR inhibitor for non-small cell lung cancer. These reports can include information on clinical timelines, regulatory interactions, and program prioritization decisions, such as the discontinuation of certain assets or the termination of license agreements.
On Stock Titan, investors can review Cullinan’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, helping to interpret complex clinical and regulatory language. Users can monitor new 8-K submissions in real time and place them in context with the company’s broader pipeline and news flow, supporting deeper analysis of CGEM’s risk profile, development progress, and strategic direction.
Jones Jeffrey Alan reported acquisition or exercise transactions in this Form 4 filing.
Cullinan Therapeutics reported that its Chief Medical Officer, Jeffrey Alan Jones, received a grant of stock options covering 300,000 shares of common stock on February 18, 2026. These options vest over four years, with one-forty-eighth of the grant vesting in equal monthly installments until the fourth anniversary of the grant date.
Cullinan Therapeutics reported that President and CEO Nadim Ahmed was granted a stock option covering 828,000 shares of common stock. The option was awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
According to the disclosure, the shares underlying the option vest over four years, with one forty-eighth of the option shares vesting in equal monthly installments until the fourth anniversary of the grant date. After this grant, the CEO held options covering 828,000 shares directly.
Cullinan Therapeutics, Inc. reported that Chief Business Officer Corrine Savill received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $0.00 per share and vest over four years in equal monthly installments of one forty-eighth of the grant.
Cullinan Therapeutics, Inc. reported that its Chief Financial Officer, Mary Kay Fenton, acquired new equity awards. She received a stock option for 137,500 shares of common stock and a separate award covering 68,750 shares of common stock. The shares underlying the restricted stock unit award vest annually over four years. The shares underlying the option vest over four years, with one forty-eighth of the optioned shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Cullinan Therapeutics, Inc. reported that its Chief Scientific Officer, Jennifer Michaelson, received new equity awards. She was granted stock options for 115,000 shares at an exercise price of $0.0000 per share and 57,500 shares of common stock as an equity award.
According to the disclosure, the 57,500 common shares are in the form of restricted stock units that vest annually over four years. The 115,000 stock options vest over four years as well, with one forty-eighth of the options vesting in equal monthly installments until the fourth anniversary of the grant date.
Cullinan Therapeutics, Inc. received an amended Schedule 13G from Biotechnology Value Fund–affiliated entities reporting a large, primarily passive stake in its common stock. As of the close of business on December 31, 2025, the BVF funds and a managed account beneficially owned an aggregate of 5,918,481 shares of Cullinan common stock, or about 9.99% of the outstanding shares, including shares issuable from Series A preferred stock.
The BVF group holds 555,935 shares of Series A convertible preferred stock, which is convertible into 5,559,350 common shares at a 10:1 ratio, but a 9.99% “Conversion Blocker” currently limits conversion to 167,798 underlying shares. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Cullinan, characterizing the position as a passive investment.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an open-market sale of common stock. On February 12, 2026, she sold 416 shares of Cullinan Therapeutics, Inc. common stock at $12.03 per share.
According to the footnote, the sale was made to cover personal income tax obligations triggered by the vesting of restricted stock units. After this transaction, Michaelson directly beneficially owns 128,219 shares of Cullinan Therapeutics common stock.
The Vanguard Group reported beneficial ownership of 3,298,504 shares of Cullinan Therapeutics Inc common stock, representing 5.58% of the class. Vanguard has shared voting power over 377,729 shares and shared dispositive power over all 3,298,504 shares, with no sole voting or dispositive power.
The shares are held on behalf of Vanguard’s clients, who are entitled to dividends and sale proceeds, and no single other person has an interest exceeding 5% of the class. Vanguard states that the position was acquired and is held in the ordinary course of business and not for the purpose of influencing control of Cullinan Therapeutics.
Cullinan Therapeutics, Inc. insider trading report: Chief Scientific Officer Jennifer Michaelson reported a sale of company stock. On January 22, 2026, she sold 4,000 shares of Cullinan Therapeutics common stock at a price of $12.30 per share in an open-market transaction. The sale was carried out under a pre-established Rule 10b5-1 trading plan that was put in place on August 7, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this transaction, Michaelson directly beneficially owned 128,635 shares of Cullinan Therapeutics common stock.
Shareholder Jennifer Michaelson has filed a Rule 144 notice to sell up to 4,000 shares of common stock of the company trading under symbol CGEM. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC, with an aggregate market value of $46,400 based on the price used in the notice, and an approximate sale date of January 22, 2026 on the NASDAQ. The filing notes that these 4,000 shares were acquired as restricted stock units from the issuer on December 11, 2023.
The notice also lists recent sales over the past three months for Michaelson’s account, including transactions of 1,345 shares for $13,458.34, 995 shares for $11,840.50, 2,148 shares for $26,592.24, and 4,000 shares for $49,200. Some of these trades are identified as being made under a Rule 10b5-1 trading plan. The filer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.